10x Genomics, Inc. (TXG) 2025 Q4 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Thank you for standing by. My name is Carly, and I will be your conference operator today. At this time, I would like to welcome everyone to the 10x Genomics fourth-quarter and full year 2025 earnings call. (Operator Instructions)

    感謝您的耐心等待。我叫卡莉,今天我將擔任你們的會議接線生。在此,我謹代表 10x Genomics 公司歡迎各位參加 2025 年第四季及全年財報電話會議。(操作說明)

  • I would now like to turn the call over to Cassie Corneau, Senior Director, Investor Relations and Strategic Finance. Please go ahead.

    現在我將把電話交給投資者關係和策略財務高級總監 Cassie Corneau。請繼續。

  • Cassie Corneau - Senior Director & Investor Relations & Strategic Finance

    Cassie Corneau - Senior Director & Investor Relations & Strategic Finance

  • Thank you, and good afternoon, everyone. Earlier today, 10x Genomics released financial results for the fourth quarter and full year ended December 31, 2025. If you have not received this news release or would like to be added to the company’s distribution list, please send an email to investors@10xgenomics.com. An archived webcast of this call will be available on the Investor tab of the company’s website, 10xgenomics.com, for at least 45 days following this call.

    謝謝大家,大家下午好。今天早些時候,10x Genomics 發布了截至 2025 年 12 月 31 日的第四季度和全年財務業績。如果您尚未收到此新聞稿,或希望加入公司投資者的郵件列表,請發送電子郵件至 investors@10xgenomics.com。本次電話會議的存檔網路直播將在公司網站 10xgenomics.com 的「投資者」標籤上保留至少 45 天。

  • Before we begin, I’d like to remind you that management will make statements during this call that are forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated, and you should not place undue reliance on forward-looking statements. Additional information regarding these risks, uncertainties, and factors that could cause results to differ appears in the press release 10x Genomics issued today, and in the documents and reports filed by 10x Genomics from time to time with the Securities and Exchange Commission. 10x Genomics disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise.

    在開始之前,我想提醒各位,管理層將在本次電話會議中發表一些符合聯邦證券法定義的前瞻性聲明。這些聲明涉及重大風險和不確定性,可能導致實際結果或事件與預期結果或事件有重大差異,因此您不應過度依賴前瞻性聲明。有關這些風險、不確定性和可能導致結果出現差異的因素的更多信息,請參閱10x Genomics今天發布的新聞稿,以及10x Genomics不時向美國證券交易委員會提交的文件和報告。 10x Genomics聲明,無論因新資訊、未來事件或其他原因,均不承擔更新或修訂任何財務預測或前瞻性聲明的意圖或義務。

  • Joining the call today are Serge Saxonov, our CEO and Co-founder; and Adam Taich, our Chief Financial Officer. We will host a question-and-answer session after our prepared remarks. We ask analysts to please keep to one question so that we may accommodate everyone in the queue.

    今天參加電話會議的有我們的執行長兼共同創辦人 Serge Saxonov,以及我們的財務長 Adam Taich。我們將在發言結束後進行問答環節。我們要求分析師每次只提一個問題,以便我們能夠滿足排隊所有人的需求。

  • With that, I will now turn the call over to Serge.

    接下來,我將把電話交給塞爾吉。

  • Serge Saxonov - Chief Executive Officer, Co-Founder, Director

    Serge Saxonov - Chief Executive Officer, Co-Founder, Director

  • Thanks, Cassie, and good afternoon, everyone. Today, I will start with an overview over our Q4 and 2025 performance. I will then talk about some of the key trends driving our business and how they position us well for future growth. Adam will then talk through the financials in more detail.

    謝謝你,卡西,大家下午好。今天,我將首先概述我們第四季和 2025 年的業績。接下來,我將談談推動我們業務發展的一些關鍵趨勢,以及這些趨勢如何使我們為未來的成長奠定良好的基礎。接下來,亞當將更詳細地講解財務狀況。

  • We delivered $166 million in revenue in the fourth quarter, exceeding the high end of our guidance range, and closed the year with $599 million in revenue, excluding $44 million of upfront revenue related to patent litigation settlements. In the fourth quarter, the operating environment remained largely unchanged from Q3. Customer spending remained subdued and capital equipment purchases remained particularly constrained. The uncertainty in research funding dynamics continues to impact customer sentiment and timing of purchasing decisions. Despite this challenging backdrop, we saw a modest budget flush toward the end of the quarter, and we continue to be encouraged by the solid underlying demand for our solutions.

    第四季度,我們實現了 1.66 億美元的收入,超過了我們預期範圍的上限;全年收入達到 5.99 億美元,不包括與專利訴訟和解相關的 4,400 萬美元預付款。第四季度,經營環境與第三季基本保持不變。顧客支出依然低迷,資本設備採購尤其受到限制。科學研究經費動態的不確定性持續影響消費者的情緒和購買決策的時機。儘管面臨這樣的挑戰性背景,我們在本季末還是看到了預算的些許充裕,而且我們解決方案的強勁潛在需求也繼續激勵著我們。

  • As I reflect on 2025 overall, I’m extremely proud of how the team executed throughout the year. While 2025 was challenging and at times highly unpredictable for our customers and the broader life sciences ecosystem, the team delivered consistently quarter after quarter. We made steady progress across the fundamental drivers of the business, advanced our product roadmap, and strengthened our financial position.

    回顧2025年,我為團隊在這一年中的出色表現感到無比自豪。儘管 2025 年對我們的客戶和更廣泛的生命科學生態系統來說充滿挑戰,有時非常難以預測,但團隊每季都持續交付成果。我們在業務的基本驅動因素方面取得了穩步進展,推進了產品路線圖,並增強了財務實力。

  • First, we saw strong momentum in key metrics that are driving the fundamentals of the business. Single-cell consumables volumes grew at a double-digit rate each quarter, driven primarily by adoption of our newer, lower-cost products, including FLEX and on-chip multiplexing. These products have expanded access, enabled new applications, and supported increased experimental volume.

    首先,我們看到推動業務基本面的關鍵指標呈現強勁成長動能。單電池耗材銷售量每季都以兩位數的速度成長,這主要得益於我們更新、成本更低的產品(包括 FLEX 和片上多工技術)的普及。這些產品擴大了應用範圍,實現了新的應用,並支持了更大的實驗規模。

  • In spatial, we delivered double-digit consumables revenue growth for the year, driven by Xenium momentum. Strong demand for Xenium translated into meaningful customer expansion throughout the year. At the same time, existing customers, including the earliest and largest users, continued to ramp their utilization. We are encouraged to see customers exploring new applications, running more experiments, and expanding the scope of their studies.

    在空間數據業務方面,在 Xenium 業務強勁成長的推動下,我們實現了年度耗材收入兩位數的成長。Xenium 的強勁需求轉化為全年客戶數量的顯著成長。同時,包括最早使用和使用量最大的用戶在內的現有客戶,繼續提高其使用率。我們很高興看到客戶探索新的應用,進行更多實驗,並擴大研究範圍。

  • Second, we delivered multiple product launches across both single-cell and spatial. Compared to even just two years ago, we have vastly expanded the capabilities of our platforms through continuous innovation. Within single cell, the launch of our next generation FLEX assay in 2025, now branded as Flex Apex, represents a meaningful step change in the capabilities of the Chromium platform. Flex Apex combines exceptionally high performance with flexible inputs, including compatibility with FFPE and fixed whole blood.

    其次,我們在單細胞和太空領域都推出了多款產品。與兩年前相比,我們透過持續創新,大大擴展了我們平台的功能。在單細胞領域,我們在 2025 年推出的下一代 FLEX 檢測方法(現在更名為 Flex Apex)代表了 Chromium 平台能力的重大飛躍。Flex Apex 結合了卓越的效能和靈活的輸入方式,包括與 FFPE 和固定全血的兼容性。

  • It supports both small exploratory experiments as well as ones with high sample counts and large numbers of cells, making it well-suited for massive-scale studies. Flex Apex delivers these features at a lower cost per experiment and is enabling expanded access to single cell, driving increased reaction volumes and supporting broader adoption across our customer base. Over a short time, we believe Flex has become a foundational assay for several of the most important growth areas in the field, including large-scale AI and Virtual Cell efforts, translational cohort studies, and biopharma discovery and development workflows.

    它既支持小型探索性實驗,也支持樣本數量多、細胞數量大的實驗,因此非常適合大規模研究。Flex Apex 以更低的單次實驗成本提供這些功能,並擴大了對單細胞的訪問,推動了反應體積的增加,並支持在我們的客戶群中更廣泛地採用。我們相信,在很短的時間內,Flex 已成為該領域幾個最重要的成長領域的基礎檢測方法,包括大規模人工智慧和虛擬細胞研究、轉化隊列研究以及生物製藥發現和開發工作流程。

  • As a result, Flex became our most popular single-cell assay by volume in the fourth quarter. We continue to hear strong feedback from customers on its ability to enable larger, more ambitious studies that were previously impractical. We look forward to seeing what our customers will accomplish as these studies progress.

    因此,Flex 在第四季成為我們銷量最高的單細胞檢測方法。我們不斷收到客戶的強烈回饋,稱其能夠進行以前不切實際的、規模更大、更具雄心的研究。我們期待看到隨著這些研究的進展,我們的客戶將會達到怎樣的成就。

  • We also had meaningful launches across our spatial platforms in 2025. Within Visium, we launched Visium HD 3 Prime to enable researchers to conduct whole transcriptome analysis across a broader range of applications and sample types. We also launched HD cell segmentation to address a key challenge in spatial analysis, helping customers visualize tissue structure in more precise detail. Within Xenium, we launched RNA and protein, enabling multimodal analysis on the same tissue section in a single integrated workflow. Together, these launches significantly expand the capabilities of our spatial portfolio.

    2025 年,我們在各個空間平台上也推出了意義重大的產品。在 Visium 內部,我們推出了 Visium HD 3 Prime,使研究人員能夠針對更廣泛的應用和樣本類型進行全轉錄組分析。我們也推出了高清細胞分割技術,以解決空間分析的一個關鍵挑戰,幫助客戶更精確地視覺化組織結構。在 Xenium 中,我們推出了 RNA 和蛋白質分析,從而能夠在單一整合工作流程中對同一組織切片進行多模態分析。這些發射活動將顯著擴展我們空間產品組合的能力。

  • As I mentioned last quarter, when it comes to spatial, we have seen a strong and growing preference among our customers towards Xenium over other approaches. This trend has continued and will likely accelerate going forward. It is a reflection of both how well the technology works, as well as the abundance of insights that scientists are gaining from the platform. Based on the feedback from our customers, it’s becoming clear Xenium is the best choice for the vast majority of customers interested in spatial.

    正如我上個季度提到的,在空間資料方面,我們看到客戶對 Xenium 的偏好日益增強,超過了其他方法。這一趨勢仍在持續,未來可能會加速發展。這不僅反映了該技術的良好運作情況,也反映了科學家從該平台獲得的豐富見解。根據客戶的回饋,很明顯,對於絕大多數對空間資料感興趣的客戶來說,Xenium 是最佳選擇。

  • And finally, we meaningfully strengthened our balance sheet over the course of the year. We grew our cash balance by more than $100 million year-over-year, reflecting disciplined cost management and focused execution across the business. We intend to continue to effectively manage costs and strategically invest in innovation and long-term growth. As we look ahead to 2026 and beyond, we believe we are well positioned to build on the progress we have made with several trends propelling growth going forward.

    最後,我們在過去一年中大幅改善了資產負債表。我們的現金餘額年增超過 1 億美元,這反映了公司內部嚴格的成本管理和專注的執行。我們將繼續有效控製成本,並對創新和長期成長進行策略性投資。展望 2026 年及以後,我們相信,憑藉推動未來成長的幾大趨勢,我們已做好充分準備,在現有進展的基礎上再創佳績。

  • First, there has been rapid parallel progress in AI and in the technologies used to measure biology. These two trends are highly complementary. Advances in single-cell and spatial technologies have increased scale, lowered costs, and made it possible to generate very large, high-quality biological data sets, while advances in AI are creating new demands for that data. Importantly, this represents a shift in how research is conducted, with AI increasingly acting as a driver of data generation rather than just a downstream analysis tool.

    首先,人工智慧和用於測量生物學的技術都取得了快速的同步發展。這兩種趨勢高度互補。單細胞和太空技術的進步提高了規模,降低了成本,並使得產生非常龐大、高品質的生物數據集成為可能,而人工智慧的進步對這些數據提出了新的需求。重要的是,這代表著研究方式的轉變,人工智慧正日益成為數據生成的驅動力,而不僅僅是下游分析工具。

  • We’re seeing growing interest in large, well-controlled studies, including perturbation-based experiments designed to capture complexity and resolve causality in biological systems. The partnerships we have announced over the past year exemplify and validate these trends. We’re supporting the Chan Zuckerberg Initiative’s Billion Cell Project, which is generating unprecedented volumes of single-cell data to fuel AI-driven biological discovery.

    我們看到人們對大型、控制良好的研究越來越感興趣,包括旨在捕捉生物系統複雜性並解決因果關係的基於擾動的實驗。我們在過去一年中宣布的合作關係反映並驗證了這些趨勢。我們正在支持 Chan Zuckerberg Initiative 的“十億細胞計劃”,該計劃正在產生前所未有的單細胞數據量,以推動人工智慧驅動的生物學發現。

  • We’re also working with the Arc Institute on the Virtual Cell Atlas, using large-scale perturbation data generated on our platforms to train and validate next-generation models of cell behavior. In addition, our collaboration with the Cancer Research Institute is focused on building high-quality, well-controlled datasets to better understand immune responses and accelerate progress in immuno-oncology. Together, these efforts illustrate how our platforms are becoming foundational for AI applications in biology.

    我們也與 Arc 研究所合作開發虛擬細胞圖譜,利用我們平台上產生的大規模擾動資料來訓練和驗證下一代細胞行為模型。此外,我們與癌症研究所的合作重點是建立高品質、控制良好的數據集,以便更好地了解免疫反應並加速免疫腫瘤學的進展。這些努力共同表明,我們的平台正在成為生物學領域人工智慧應用的基礎。

  • Another area that has become increasingly important for us, and one we see as a meaningful growth driver going forward is translational research. We’re seeing growth in translational research for three fundamental reasons. First, in multiple therapeutic areas like oncology and autoimmunity, we have an increasing number of therapies, but only a limited understanding of which therapies are appropriate for which patient.

    轉化研究對我們來說變得越來越重要,我們認為它將成為未來重要的成長動力。轉化研究的成長主要有三個原因。首先,在腫瘤學和自體免疫學等多個治療領域,我們擁有越來越多的療法,但對於哪些療法適合哪些患者,我們卻知之甚少。

  • Second, there is increasing evidence from literature that single-cell and spatial are very promising approaches for discovering actionable biomarkers and signatures of response. Third, our platforms have made big advances in scale, cost, and robustness, as well as in compatibility with critical clinical samples, most importantly, FFPE and whole blood. It is now straightforward to run large-scale cohort studies, and this is precisely what many of our customers have been doing. We announced a number of initiatives last year with academic medical centers and with industry partners to undertake large-scale translational studies.

    其次,越來越多的文獻證據表明,單細胞和空間方法是發現可操作的生物標記和反應特徵的非常有前景的方法。第三,我們的平台在規模、成本和穩健性方面取得了巨大進步,並且在與關鍵臨床樣本(尤其是 FFPE 和全血)的兼容性方面也取得了巨大進步。現在進行大規模隊列研究變得非常簡單,而這正是我們許多客戶一直在做的事情。去年,我們與學術醫療中心和產業合作夥伴宣布了一系列舉措,以進行大規模轉化研究。

  • Translational research is also an important driver of biopharma adoption. Single-cell and spatial technologies have relevance across the drug development continuum, but the largest opportunity lies in later translational stages, where biomarker strategies are essential to understand patient response and potential toxicity. This is where our solutions can meaningfully improve the probability of success and where we expect to increasingly focus our efforts.

    轉化研究也是推動生物製藥應用的重要因素。單細胞和太空技術在整個藥物開發過程中都具有相關性,但最大的機會在於後期的轉化階段,生物標記策略對於了解患者的反應和潛在的毒性至關重要。我們的解決方案可以顯著提高成功的機率,這也是我們未來將重點放在的領域。

  • And finally, as this translational work has been picking up, we’re hearing growing interest from customers in applying our technologies to patient care. Based on that, as well as a growing body of scientific literature, we believe there is a significant potential for single-cell and spatial biology in diagnostic applications realizing that potential will require the generation of robust clinical evidence and deployment of these technologies in the clinical setting. To enable clinical applications of single-cell and spatial analysis, we’re pursuing two parallel paths. First, we’re continuing to support our customers in generating clinical evidence, and we’ll collaborate with them to enable clinical deployment in the future.

    最後,隨著轉化工作的開展,我們聽到客戶對將我們的技術應用於患者護理的興趣日益濃厚。基於此以及不斷增長的科學文獻,我們認為單細胞和太空生物學在診斷應用方面具有巨大的潛力,而要實現這一潛力,需要產生可靠的臨床證據並在臨床環境中部署這些技術。為了實現單細胞和空間分析的臨床應用,我們正在探索兩條平行路徑。首先,我們將繼續支持我們的客戶產生臨床證據,我們將與他們合作,以在未來實現臨床部署。

  • In parallel, we believe we ourselves are in a unique position to accelerate the arrival of some of the highest impact diagnostics, given our technology leadership, understanding of applications, and strong position in the research ecosystem. As part of the strategy, we recently announced two collaborations with leading academic medical centers to support clinical evidence generation. With Dana-Farber Cancer Institute, we’re focused on tissue-based spatial profiling to support biomarker discovery and therapy selection in oncology. With Brigham and Women’s Hospital, we’re pursuing blood-based monitoring approaches to enable longitudinal assessment of disease activity and treatment response in autoimmune disease.

    同時,我們相信,憑藉我們的技術領先地位、對應用的理解以及在研究生態系統中的強大地位,我們自身處於獨特的優勢,能夠加速一些最具影響力的診斷技術的到來。作為該策略的一部分,我們最近宣布與兩家領先的學術醫療中心合作,以支持臨床證據的產生。我們與丹娜-法伯癌症研究所合作,專注於基於組織的空間分析,以支持腫瘤學中的生物標記發現和治療選擇。我們正與布里格姆婦女醫院合作,探索以血液為基礎的監測方法,以便對自體免疫疾病的疾病活動和治療反應進行縱向評估。

  • We expect to expand this set of collaborations over time as we continue to build programs across various indications. We’re also building out a clear laboratory to enable clinical deployment of the resulting tests.

    隨著我們不斷在各個適應症領域開展項目,我們希望未來能夠擴大此類合作的範圍。我們也正在建造一個透明的實驗室,以便將由此產生的檢測方法應用於臨床。

  • Stepping back and setting aside the current macro environment, it’s hard not to be excited by our position of the company. We believe we’re at the nexus of some of the most important trends our industry has ever seen. We have a powerful innovation engine, a high-performing organization, and a strong balance sheet. We’re focused on delivering continuous innovation across our platforms and believe 2026 will be a particularly exciting year as we advance our roadmap and bring new capabilities to our customers. I feel incredibly privileged by the position we’re in and optimistic about the opportunity ahead.

    拋開當前的宏觀環境不談,很難不對公司目前的市場地位感到興奮。我們相信,我們正處於我們行業有史以來一些最重要趨勢的交匯點。我們擁有強大的創新引擎、高效率的組織和穩健的資產負債表。我們致力於在各個平台上持續創新,並相信 2026 年將是令人振奮的一年,因為我們將推進我們的路線圖,並為我們的客戶帶來新的功能。我為我們目前所處的地位感到無比榮幸,並對未來的機會充滿信心。

  • With that, I will turn the call over to Adam.

    接下來,我會把電話交給亞當。

  • Adam Taich - Chief Financial Officer

    Adam Taich - Chief Financial Officer

  • Thanks, Serge. Before reviewing the fourth quarter results, I want to take a moment to reflect on 2025 as a whole. Despite a highly volatile external environment that drove some variability in quarterly revenue, we exited the year in a strong financial position. We remained disciplined on spending, strengthened our operating foundation, and meaningfully increased our cash balance, positioning the company for a strong future.

    謝謝你,塞爾吉。在回顧第四季業績之前,我想花點時間展望一下 2025 年的整體情況。儘管外部環境高度不穩定,導致季度營收出現一定波動,但我們年底的財務狀況依然強勁。我們嚴格控制支出,加強了營運基礎,並大幅增加了現金餘額,為公司未來的強勁發展奠定了基礎。

  • With that, I will now focus my commentary on our fourth quarter financial results and the related drivers. Details of our full year results can be found in today’s press release. All growth rates referenced reflect year-over-year comparisons, unless otherwise noted. Revenue for the fourth quarter was $166 million. This represents 1% growth over the prior year and exceeded the high end of our guidance range.

    接下來,我將重點放在我們第四季的財務表現及其相關驅動因素。有關我們全年業績的詳情,請參閱今天的新聞稿。除非另有說明,所有提及的成長率均反映同比比較。第四季營收為1.66億美元。這比上年增長了 1%,超過了我們預期範圍的上限。

  • Our fourth quarter results reflected a challenging operating environment, balanced by continued momentum in the business. As mentioned during our remarks at a recent investor conference, we also saw some unanticipated budget flush late in the quarter, which partially contributed to performance in the period.

    我們第四季的業績反映了充滿挑戰的經營環境,但業務的持續成長動能彌補了這一不足。正如我們在最近的投資者會議上所提到的,本季末我們也看到了一些意料之外的預算盈餘,這在一定程度上促進了該季度的業績。

  • Total consumables revenue was up 6%, with growth in both single-cell and spatial. Single-cell consumables revenue was up 3%, supported by double-digit growth in reaction volumes, in part due to our lower-priced Flex assay. Spatial consumables continued to perform well in the quarter, with revenue up 14%, driven by Xenium consumables. Total instrument revenue declined 36%, with Chromium instrument revenue down 44% and spatial instrument revenue down 30%. Consistent with the patterns we saw throughout 2025, instrument revenue in the fourth quarter remained under pressure, given ongoing funding challenges for capital equipment, though we did see a sequential uptick due to year-end capital spending.

    耗材總收入成長了 6%,單細胞和空間數據均實現了成長。單細胞耗材收入成長了 3%,這得益於反應量兩位數的成長,部分原因是由於我們價格較低的 Flex 檢測。本季空間耗材業務持續表現良好,營收成長 14%,主要得益於 Xenium 耗材的成長。儀器總收入下降了 36%,其中 Chromium 儀器收入下降了 44%,太空儀器收入下降了 30%。與 2025 年全年的趨勢一致,由於資本設備資金持續面臨挑戰,第四季度儀器收入仍然承壓,儘管由於年底資本支出,我們確實看到了環比增長。

  • Looking at revenue by geography, Americas revenue declined 6%, while EMEA and APAC grew 7% and 9%, respectively. While the Americas region remained muted amid continued softness in the US academic and government funding environment, EMEA performed better than expected, driven by some late quarter orders as customers worked through year-end spending. APAC had a solid quarter, consistent with our expectations.

    從地理上看收入,美洲的收入下降了 6%,而歐洲、中東和非洲地區以及亞太地區的收入分別成長了 7% 和 9%。儘管由於美國學術界和政府資助環境持續疲軟,美洲地區表現平淡,但歐洲、中東和非洲地區 (EMEA) 的表現好於預期,這得益於一些季度末訂單,因為客戶正在處理年底支出。亞太地區本季表現穩健,符合我們的預期。

  • Turning to the rest of the P&L. Gross margin was 68% for the fourth quarter of 2025, as compared to 67% for the prior year period. The increase was primarily driven by lower inventory write-downs, as well as lower royalty and warranty costs, partially offset by higher manufacturing costs. On the operating expense side, we continued to execute with a strong focus on operating efficiency and cost discipline.

    接下來來看損益表的其餘部分。2025年第四季毛利率為68%,而上年同期為67%。此次成長主要得益於庫存減損減少以及特許權使用費和保固費用降低,但部分被更高的製造成本所抵銷。在營運費用方面,我們持續高度重視營運效率和成本控制。

  • Consistent with this focus, total operating expenses decreased 18% in the fourth quarter, primarily driven by lower outside legal expenses and lower personnel costs. We ended the year with $523 million in cash, cash equivalents, and marketable securities, up $130 million from the end of 2024.

    與此重點一致,第四季總營運費用下降了 18%,主要原因是外部法律費用和人員成本降低。截至年底,我們持有現金、現金等價物和有價證券共 5.23 億美元,比 2024 年底增加了 1.3 億美元。

  • Turning to our outlook for 2026. While the funding environment continues to be muted, it has reached a measure of stability that we believe supports reinstating full-year revenue guidance. We expect 2026 revenue to be in the range of $600 million to $625 million. Excluding upfront revenue related to patent litigation settlements in 2025, this represents 0% to 4% growth over the full year 2025.

    接下來展望2026年。儘管融資環境依然低迷,但已達到一定程度的穩定,我們認為這足以支持我們恢復全年營收預期。我們預計 2026 年的營收將在 6 億美元至 6.25 億美元之間。若排除 2025 年與專利訴訟和解相關的預付收入,則 2025 年全年成長率為 0% 至 4%。

  • At the midpoint, our guidance implies a continuation of the trends we saw throughout 2025, including double-digit growth for both single-cell consumables reactions and spatial consumables revenue. The guidance range also assumes CapEx funding remains constrained, which will continue to put downward pressure on instrument revenue.

    到中期,我們的指導意見意味著我們在 2025 年看到的趨勢將持續,包括單細胞耗材反應和空間耗材收入的兩位數成長。此指引範圍也假設資本支出資金仍受限,這將繼續對工具收入構成下行壓力。

  • We expect the overall environment to be consistent with the second half of 2025, with customers remaining cautious in their purchasing decisions. We were encouraged to see the recent NIH budget approval, as well as decisions on both indirect funding and multi-year funding as part of the bill. Notwithstanding this improved clarity, there is still significant systemic turbulence in research funding dynamics that continue to impact customer sentiment and timing of purchasing decisions.

    我們預期整體環境將與 2025 年下半年保持一致,消費者在購買決策方面仍將保持謹慎。我們很欣慰地看到,美國國立衛生研究院 (NIH) 近期批准了預算,並且該法案中還包含了關於間接資助和多年期資助的決定。儘管情況有所改善,但科學研究經費動態方面仍存在顯著的系統性動盪,這繼續影響著消費者的情緒和購買決策的時機。

  • Additionally, as we think about the cadence of the year, we anticipate first quarter revenue to be a larger % of full year revenue as compared to prior years. This is partially driven by orders received late in the fourth quarter that were shipped in January.

    此外,考慮到全年的節奏,我們預計第一季營收將佔全年收入的比例將比往年更高。部分原因是因為第四季末收到的訂單在1月出貨所致。

  • Moving to the rest of the P&L, we expect our overall financial profile to further strengthen in 2026. The cost discipline we’ve embedded over the past year has translated into tangible operating efficiencies. Moving forward, we expect to sustain these productivity gains while continuing to drive improvement across the business and advancing a strong slate of product introductions.

    從損益表的其他部分來看,我們預計 2026 年我們的整體財務狀況將進一步增強。過去一年我們貫徹的成本控制措施已轉化為實際的營運效率提升。展望未來,我們期望保持這些生產力提升,同時繼續推動業務的全面改進,並推出一系列強大的產品。

  • With that, I will turn the call back to Serge.

    這樣,我就把電話轉回給塞爾吉了。

  • Serge Saxonov - Chief Executive Officer, Co-Founder, Director

    Serge Saxonov - Chief Executive Officer, Co-Founder, Director

  • Thanks, Adam. Before we turn it over for questions, I’d like to acknowledge just how tough 2025 was for our customers and take a moment to thank the 10x team. Despite all the turbulence, you stayed focused on our work, our customers, and our mission. It hasn’t been easy, but the progress you’ve made on multiple fronts is nothing short of remarkable. As a company, we’re stronger than we’ve ever been. We’re entering 2026 with great momentum and a landscape of profoundly important opportunities ahead of us. Thank you for everything you do.

    謝謝你,亞當。在進入問答環節之前,我想表達一下對客戶而言,2025 年是多麼艱難的一年,並藉此機會感謝 10x 團隊。儘管經歷了種種動盪,你們始終專注於我們的工作、我們的客戶和我們的使命。雖然不容易,但你在多個方面取得的進步堪稱卓越。作為一家公司,我們比以往任何時候都更強大。我們帶著強勁的發展動能邁入 2026 年,眼前充滿了意義深遠的重要機會。感謝你所做的一切。

  • With that, we will now open it up for questions. Operator?

    接下來,我們將開放提問環節。操作員?

  • Operator

    Operator

  • (Operator Instructions)

    (操作說明)

  • Tycho Peterson, Jefferies.

    泰科·彼得森,傑富瑞集團。

  • Tycho Peterson - Analyst

    Tycho Peterson - Analyst

  • Serge, just wondering, a month and a half or so into the year here, if you can maybe just comment on anything on ordering patterns that you’re seeing right now, and then give us a quick walk on what you’re baking in for academic and pharma, in particular, around some of these larger Perturb-seq type studies, and then also clinical. I mean, you’re not the first company today to mention single cell and spatial on clinical. So I’m just curious how you think about the timeline of that opportunity.

    Serge,我想問,今年已經過去一個半月了,您能否就您目前看到的訂購模式發表一些評論,然後簡要介紹一下您正在為學術界和製藥業,特別是圍繞一些大型的 Perturb-seq 類型研究以及臨床研究,制定哪些計劃。我的意思是,你們並不是今天第一家在臨床上提及單細胞和太空技術的公司。所以我很好奇你如何看待這個機會的時間安排。

  • Serge Saxonov - Chief Executive Officer, Co-Founder, Director

    Serge Saxonov - Chief Executive Officer, Co-Founder, Director

  • Yeah, several questions embedded in there. So first of all, just the general kind of sentiment out there and the customer orientation. Yeah, we would say that, it’s been -- the environment has been similar -- is similar to what it has been for the past couple of quarters. The second half of 2025 is pretty similar to what we’re seeing now and what we expect to see kind of throughout the rest of the year. Certainly, it’s been gradually improving, certainly compared to the first half of 2025.

    是的,裡麵包含好幾個問題。首先,我們來看看市場上的普遍情緒以及顧客導向。是的,我們認為,環境一直與過去幾季的情況類似。2025 年下半年的情況與我們現在看到的情況非常相似,也與我們預計在今年剩餘時間看到的情況非常相似。當然,情況一直在逐步改善,尤其是與 2025 年上半年相比。

  • But there’s a lot of uncertainty still remaining and caution among our customers. There’s a number of issues that are going on in the academic sphere, the US academic funding, when it comes to staffing, when it comes to the timing of disbursements, criteria by which grants are reviewed and judged, universities are uncertain around their budgets, multi-year funding, budget resolutions, things like that.

    但目前仍存在諸多不確定因素,我們的客戶也保持謹慎態度。學術界正在發生許多問題,例如美國的學術經費,包括人員、撥款時間、撥款審查和評判標準,大學在預算、多年期撥款、預算決議等方面都存在不確定性。

  • So overall, I think the environment, like Adam mentioned, is generally pretty steady, and not as bad, again, as it was in the first half of last year, but there’s still a lot of uncertainty remaining. On -- as far as this year is concerned and kind of the drivers going forward, certainly we’re excited. As I mentioned earlier in my remarks, there’s a big wave of AI-driven projects, Perturb-seq type applications, and our products, especially Flex are incredibly well suited for that purpose.

    所以總的來說,我認為正如亞當提到的那樣,環境總體上相當穩定,而且沒有去年上半年那麼糟糕,但仍然存在許多不確定因素。至於今年以及未來的發展方向,我們當然感到興奮。正如我之前在演講中提到的,現在湧現出大量人工智慧驅動的項目、擾動序列類型的應用,而我們的產品,特別是 Flex,非常適合用於此目的。

  • And you can actually see that now coming out in preprints, other publications, validating the premise. And so we certainly have a lot of excitement that we see around this application, around these trends. They were meaningful, relatively small percentage of our business last year, and we expect it to keep growing going forward. And I think what’s particularly exciting to us is that there is -- as you look to the future, the upside is enormous. There’s like really no credible ceiling to how much data people are looking to generate and how much data would be useful to generate for these AI models.

    現在你可以在預印本和其他出版物中看到這一點,驗證了這個前提。因此,我們對這項應用以及這些趨勢感到非常興奮。去年,它們在我們業務中所佔比例相對較小,但意義重大,我們預計未來這一比例將繼續成長。我覺得最讓我們興奮的是──展望未來,它的發展潛力大。人們想要產生的資料量以及對這些人工智慧模型有用的資料量,似乎真的沒有一個可信的上限。

  • Operator

    Operator

  • Doug Schenkel, Wolfe Research.

    道格‧申克爾,沃爾夫研究中心。

  • Doug Schenkel - Equity Analyst

    Doug Schenkel - Equity Analyst

  • First on pricing, it sounds like single-cell consumable revenue grew and reaction volume was up. What I’m having a hard time figuring out is, was volume growth enough to offset pricing? I guess in a long-winded way, what I’m trying to get at is, how should we think about how volume and price trended into year-end, and then how are you contemplating those factors in guidance?

    首先是定價方面,單細胞耗材收入似乎有所成長,反應量也有所增加。我很難理解的是,銷售成長是否足以抵銷價格上漲的影響?我想用比較囉嗦的方式來說,我想表達的是,我們該如何看待年底的銷售和價格趨勢,以及你們在業績指引中是如何考慮這些因素的?

  • Serge Saxonov - Chief Executive Officer, Co-Founder, Director

    Serge Saxonov - Chief Executive Officer, Co-Founder, Director

  • Yeah. So let me take that one, Doug. So, yeah, I think, maybe starting with Q4. So when we think about the full year, full year, 2025 revenue growth was 22%. In Q4, in part due to the launch of Flex Apex, we had 30%-plus volume growth. So really nice trend sort of rounding out the year. So when we’re thinking about that balance for 2026, I think the best way to think about it is Chromium consumables, if you think about the midpoint of our guide, it’s flat, right? So essentially at about flat, and there’s a bunch of different combinations and permutations that could get you there, depending on sort of the mix of product and various volumes.

    是的。那我就來回答這個問題吧,道格。所以,是的,我想,或許從第四季開始。因此,當我們考慮全年時,2025 年全年營收成長率為 22%。第四季度,部分原因是 Flex Apex 的推出,我們的銷售成長超過 30%。所以,這真是個不錯的趨勢,為這一年畫上了圓滿的句點。所以,當我們考慮 2026 年的平衡時,我認為最好的考慮方式是鉻消耗品,如果你想想我們指南的中點,它是平穩的,對吧?所以基本上是平穩的,而且有很多不同的組合和排列可以達到這個目標,這取決於產品的組合和各種數量。

  • But that’s the way that we’re thinking about the guide and the components of the guide. So we talked about continued pressure as it relates to CapEx. We talked about double-digit ongoing strength in our spatial consumables. And if you sort of think about the chromium consumables business at 0% growth, that’s sort of roughly where we are. There’s a couple of different ways you can probably get there, based on product uptake, particularly around the Flex franchise, but that’s really where we’re thinking about 2026.

    但這就是我們對指南及其組成部分的思考方式。所以我們討論了與資本支出相關的持續壓力。我們討論了空間消耗品持續兩位數成長的趨勢。如果你把鉻耗材業務的成長率想像成 0%,那大概就是我們現在的處境。根據產品接受度,特別是 Flex 系列產品,可能有幾種不同的方法可以實現這一目標,但這正是我們 2026 年真正考慮的方向。

  • Operator

    Operator

  • Puneet Sauda, Leerink.

    Puneet Sauda,Leerink。

  • Puneet Souda - Analyst

    Puneet Souda - Analyst

  • Let me ask mine on Flex Apex. So it appears that Flex V2 is rebranded as Apex. Maybe just a quick clarification there. What was the mix of Flex V1 versus V2 in the fourth quarter? And I’m wondering if you can take a minute and talk about how are you thinking about Flex, I mean, the Apex product, playing out throughout 2026, how pricing is going to be impacted as the adoption for that grows? And how should we think about the 3 prime, 5 prime GenX kits switching over to potentially Apex and how to think about the pricing headwind from that, because that could be fairly meaningful. Just want to understand those drivers and sort of the timing of how that plays out.

    讓我問問我的 Flex Apex 用戶。看來 Flex V2 已經更名為 Apex。或許需要簡單澄清一下。第四季 Flex V1 與 V2 的比例是多少?我想請您花一分鐘時間談談您對 Flex(即 Apex 產品)的看法,以及在 2026 年,隨著其採用率的提高,定價將受到怎樣的影響?那麼我們應該如何看待 3 Prime、5 Prime GenX 套件可能切換到 Apex,以及由此帶來的價格不利影響,因為這可能會產生相當大的影響。我只是想了解這些驅動因素以及它們如何發揮作用的時間節點。

  • Serge Saxonov - Chief Executive Officer, Co-Founder, Director

    Serge Saxonov - Chief Executive Officer, Co-Founder, Director

  • Yeah, so first of all, yes, I mean, Flex Apex, we launched it last quarter in Q4, and was really strong out of the gate. It’s too early to talk about sort of the breakdown of the different versions of Flex within the larger assay category, but obviously did really well. And also now getting great feedback as customers are actually running through the experiments, generating data, and looking forward to ramping and to increasing their usage. So, all kind of great trends. Again, I would emphasize that it’s still very early. It was only partially available in Q4, and so still -- we’re still very much in the early part of that adoption curve.

    是的,首先,是的,我的意思是,Flex Apex,我們上個季度(第四季)推出了它,而且一開始就表現非常強勁。現在談論 Flex 在大檢測類別中不同版本的具體情況還為時過早,但顯然它的表現非常出色。目前我們也收到了很好的回饋,因為客戶們正在實際進行實驗,產生數據,並期待擴大規模和增加使用量。所以,各種各樣的好趨勢。我再次強調,現在還為時過早。第四季度它只是部分可用,所以——我們仍然處於普及曲線的早期階段。

  • Now, as we think about going forward, I think it’s kind of important to delineate the different buckets of single cell use kind of and going back to your question around where Flex is gonna get adoption. So first of all, there’s a lot of new use cases, and it’s an ambiguous trend here when we hear from customers that this Flex Apex is now opening up new opportunities, new experiments, that they -- new studies that they weren’t contemplating before. And so that is purely additive, and that’s where our commercial team is focused on, is driving these applications, enabling these new use cases, enabling all this additional volume.

    現在,當我們考慮未來發展方向時,我認為區分單電池使用的不同類別非常重要,回到你關於 Flex 將在哪些領域得到應用的問題。首先,有許多新的用例,從客戶那裡聽到的是,Flex Apex 現在正在開闢新的機會、新的實驗,以及他們以前從未考慮過的新研究,這是一種模棱兩可的趨勢。因此,這完全是新增的,而這正是我們商業團隊的重點,即推動這些應用,實現這些新的用例,實現所有這些額外的銷售。

  • Also, yeah, there’s a large fraction of single cell use where people are just not going to switch. Back to your question about universal 5 prime, 3 prime. We have lots of other products that are uniquely necessary for the use cases that researchers are using it for. Also established workflows where they’re not looking to switch. And then finally, there’s people that are going to switch either from the earlier versions of Flex or from some of the other products, like 3 prime.

    是的,單電池使用率很高,很大一部分人根本不會更換電池。回到你關於宇宙5質數、3質數的問題。我們還有很多其他產品,這些產品對於研究人員的特定使用情境是必不可少的。他們也已經建立了工作流程,並不打算改變。最後,還有一些人會從早期版本的 Flex 或其他產品(如 3 prime)改用 Flex。

  • What we’re hearing is that some of them will just spend the same amount of money and the same budgets that they have, but just run more samples, and some will run the same number of samples but pay less per sample. It’s definitely kind of a headwind that we’re watching carefully. But one thing I just want to emphasize that it’s important to appreciate that it’s not just single price drop across the board. There’s multiple dynamics here, and multiple categories of customers. And our focus is fundamentally on driving additional extra volume.

    我們了解到,有些公司會花費相同的資金和預算,但增加樣品檢測的數量;而有些公司會檢測相同數量的樣品,但每個樣品的檢測費用會降低。這無疑是一股逆風,我們正在密切關注。但我想強調一點,那就是需要理解,這並非是所有商品價格的全面下調。這裡存在著多種動態因素,以及多種類型的客戶。我們的重點從根本上來說是為了推動銷售成長。

  • Clearly, that was a good trend that we saw in Q4. As Adam mentioned, out of the gate, there was a greater than 30% reaction volume growth and it’s a not unreasonable kind of anchor point to think about 2026.

    顯然,這是我們在第四季度看到的良好趨勢。正如亞當所提到的,一開始反應量就增加了 30% 以上,這是一個值得考慮的 2026 年的錨點。

  • Operator

    Operator

  • Dan Arias, Stifel.

    Dan Arias,Stifel。

  • Daniel Arias - Analyst

    Daniel Arias - Analyst

  • Serge, can you maybe just talk about the push into the clinical translational space? That sounds like it’s gonna get going with these institutions that you talked about last month. What are your expectations when it comes to those types of customers using single-cell and spatial products? And then how broad is that push gonna be this year? Is it sort of meant to be a pilot program of sorts with those hospitals, or is it part of a larger commercial effort?

    Serge,您能否談談進軍臨床轉化領域的進展?聽起來像是你上個月提到的那些機構要開始運作了。對於使用單小區和空間產品的這類客戶,您有何期望?那麼,今年的推廣力道會有多大?這是否意在與這些醫院進行某種試點項目,還是更大規模商業計畫的一部分?

  • Serge Saxonov - Chief Executive Officer, Co-Founder, Director

    Serge Saxonov - Chief Executive Officer, Co-Founder, Director

  • So there’s actually two separate sort of categories of efforts that we have. There is a future-looking set of initiatives that we’re undertaking to stand up future clinical applications for diagnostics in the future, using single-cell and spatial technologies. We’re super excited about them. A lot of it is driven by just the interest we see from customers and from physicians that are out there.

    所以,實際上我們有兩個不同的努力類別。我們正在進行一系列著眼於未來的舉措,旨在利用單細胞和太空技術,為未來的臨床診斷應用奠定基礎。我們對此感到非常興奮。很大程度上,這都源自於我們從客戶和醫生那裡看到的興趣。

  • And as I mentioned earlier, our goal here is to kind of pursue a hybrid strategy, where we enable our existing customers to develop clinical evidence and to ultimately deploy these technologies in a clinical setting. And we’re also undertaking our own efforts to build up clinical evidence and build up a CLIA lab to deploy these tests. We believe we can do this particularly efficiently, leveraging our existing assets, and very excited about these efforts. They are future-looking.

    正如我之前提到的,我們的目標是採取一種混合策略,讓現有客戶能夠開發臨床證據,並最終在臨床環境中部署這些技術。我們也在努力累積臨床證據,並建立一個 CLIA 實驗室來部署這些測試。我們相信,我們可以利用現有資源,有效率地完成這項工作,並對這些努力感到非常興奮。他們具有前瞻性。

  • That said, they’re also synergistic with our current business because they provide a measure of validation to where this technology is going. They give people, customers comfort in adopting single-cell and spatial in research, in the current research applications, and in drug development applications. And then, kind of the second category of efforts, more near-term around, again, translational research. This is where our products are already being used and there’s potential for a lot more.

    也就是說,它們也與我們目前的業務具有協同效應,因為它們為這項技術的發展方向提供了一定程度的驗證。它們讓人們和客戶在研究、當前研究應用和藥物開發應用中採用單細胞和太空技術時感到安心。然後,第二類努力,更偏向近期進行的轉化研究。我們的產品目前已經在這些領域得到應用,而且還有很大的發展潛力。

  • Again, there’s a fair amount of kind of our single-cell products and spatial being used on patient cohorts to look for biomarkers to drive drug discovery. But the promise here is to really scale this up and make it routine and go to more customers with much larger volumes. I would say that the opportunity there is at least as big as what we have seen in basic science, and our products now are in a place where they can support these kinds of applications, these kinds of efforts, and it is a big focus for our commercial team this year as well.

    再次強調,我們相當多的單細胞產品和空間數據正被用於患者群體,以尋找生物標記來推動藥物發現。但這裡的願景是真正擴大規模,使其成為常規操作,並服務更多客戶,實現更大的交易量。我認為,這方面的機會至少與我們在基礎科學領域看到的機會一樣大,而我們的產品現在能夠支援這類應用和這類研究,這也是我們商業團隊今年的重點工作。

  • Operator

    Operator

  • Kyle Mikson, Canaccord.

    Kyle Mikson,Canaccord。

  • Kyle Mikson - Equity Analyst

    Kyle Mikson - Equity Analyst

  • The comments on consumables and reaction growth was helpful, but on instruments and this guidance here, just could you talk about which franchise you think will experience the largest impact from the CapEx headwinds in 2026?

    關於消耗品和反應成長的評論很有幫助,但是關於儀器和這裡的指導,您能否談談您認為哪個特許經營權在 2026 年會受到資本支出逆風的最大影響?

  • And then secondly, just on translational revenue with the new biopharma-focused commercial team, were there any, like, proof statements in 2025 that give you confidence that biopharma can break through like 30% of revenue in 2026, get to maybe half of revenue over time?

    其次,就新的生物製藥商業團隊的轉化收入而言,2025 年是否有任何證據聲明,讓您有信心生物製藥可以在 2026 年突破 30% 的收入,並隨著時間的推移達到一半的收入?

  • Serge Saxonov - Chief Executive Officer, Co-Founder, Director

    Serge Saxonov - Chief Executive Officer, Co-Founder, Director

  • So let me pick up that second question first, Kyle. So yes, we’re very excited about the potential for translational research, and I would say that’s both in sort of in academia and medical centers, academic medical centers, and in biopharma. Our eventual goal -- and you’re right, is to drive to a place where some point half of our revenue is driven by biopharma. We’re not making a claim about doing this year, clearly, but we expect to take steps in that direction this year.

    凱爾,那我就先回答第二個問題吧。所以,是的,我們對轉化研究的潛力感到非常興奮,我認為這種潛力既存在於學術界和醫療中心,也存在於學術醫療中心和生物製藥領域。我們的最終目標——你說得對——是努力使生物製藥業務貢獻我們一半的收入。我們顯然沒有聲稱今年一定能做到,但我們預計今年會朝著這個方向邁出步伐。

  • We talked about adoption in large-scale translational research projects last year. Quite a few of them publicly announced, and even this year, we’ve already announced a number of them. I think it’s pretty clear that this is just the beginning. When we talk to biopharma customers, there’s clearly potential for single-cell use and spatial use all across the drug development continuum.

    去年我們討論了大規模轉化研究計畫中的收養問題。其中不少已經公開宣布,甚至今年,我們也已經宣布了其中一些。我認為很明顯,這只是個開始。當我們與生物製藥客戶交談時,很明顯,單細胞應用和空間應用在整個藥物開發過程中都具有潛力。

  • We have been very much kind of historically focused on the early discovery stage, and now there’s potential to expand downstream into translational use cases, into biomarker programs. And both the dollars that are spent there and the size of the cohort, the size of experiments is just much larger. And so that presents a really great opportunity for us, for which there is tangible, yet at this point early evidence of potential. And like I said earlier, our products are now at a place where they’re perfectly suited for those applications.

    我們一直以來都非常注重早期發現階段,現在有可能向下游擴展到轉化應用案例,進入生物標記計畫。無論是投入的資金,或是研究對象規模,實驗規模都大得多。因此,這為我們提供了一個非常好的機會,目前已經有一些切實的、但尚處於早期階段的證據表明其具有潛力。正如我之前所說,我們的產品現在已經完全適用於這些應用場景。

  • Adam Taich - Chief Financial Officer

    Adam Taich - Chief Financial Officer

  • I can take the second piece of the question, Kyle, around CapEx. I mean, what we’re seeing broadly, and anticipating in our guides, is that the CapEx funding environment just broadly remains constrained. That said, there is typically more pressure on the higher end side of CapEx.

    凱爾,關於問題的第二個部分,我可以從資本支出的角度來回答。我的意思是,我們總體上看到,並且在指南中也預測到,資本支出融資環境總體上仍然受到限制。也就是說,資本支出的高端部分通常會面臨更大的壓力。

  • We actually grew Chromium instruments on a unit basis year-over-year from 2024 to 2025. We did that in large part, and we’ll continue to do so as needed in 2026 here, by working with our customers, trying to ensure that we’re getting any of the capital barriers they may have sort of out of the way. And if we can get package-type deals where there’s a consumables commitment, it ends up working out well, given the margin profile on our consumables. We’ll continue to do that into '26.

    從 2024 年到 2025 年,我們 Chromium 儀器的銷量實際上逐年增長。我們在很大程度上做到了這一點,而且在 2026 年,我們將根據需要繼續這樣做,透過與客戶合作,努力確保我們能夠消除他們可能遇到的任何資金障礙。如果我們能達成包含耗材承諾的打包交易,考慮到我們耗材的利潤率,最終結果會很不錯。我們將繼續這樣做,直到 2026 年。

  • Operator

    Operator

  • Dan Brennan, TD Cowen.

    丹·布倫南,TD Cowen。

  • Daniel Brennan - Analyst

    Daniel Brennan - Analyst

  • Maybe one on the price volume again for Chromium. So is it fair to think that in the flat Chromium consumable guide, it’s kind of a similar math, maybe volumes up 20, price down 20? I know the price is kind of a tricky thing because it’s not like for like, but I guess that’s the first question.

    或許鉻的價格成交量又會再次出現問題。那麼,在 Chromium 的扁平化消耗指南中,是否可以這樣認為,其計算方式也類似,例如銷量上升 20,價格下降 20%?我知道價格是個比較棘手的問題,因為它不是同類產品之間的比較,但我想這是第一個問題。

  • The second one is just, while NIH is still under pressure, albeit hopefully getting better, you put up good numbers overall in China and EMEA. So I’m wondering if you could speak a little bit to how you’re thinking about the outlook, what’s baked into the guide between the different academic customer groups in different regions even if US is weak, like, are those other regions, could they pick it up?

    第二點是,雖然美國國立衛生研究院 (NIH) 仍然面臨壓力,但希望情況會好轉,你們在中國和歐洲、中東及非洲地區 (EMEA) 的整體數據都很好。所以我想知道您能否談談您對前景的看法,以及在不同地區的不同學術客戶群之間,即使美國市場較弱,該指南中又包含了哪些內容,例如,其他地區能否接受該指南?

  • Then final one is just the balance sheet, really strong, great cash generation. What are the plans with the cash that you’re building as we look ahead in '26?

    最後一點就是資產負債表,非常強勁,現金流產生能力很強。展望2026年,你們打算如何運用累積的現金?

  • Serge Saxonov - Chief Executive Officer, Co-Founder, Director

    Serge Saxonov - Chief Executive Officer, Co-Founder, Director

  • Well, so, yeah, maybe I’ll start with that last question. Yeah, look, we’re very happy to have the balance sheet. Obviously, that was a big focus for us last year for multiple reasons. Big one, just to give us a cushion. The environment was highly, highly unpredictable, and we wanted to make sure that we can execute on our priorities regardless of what happens to the external environment.

    嗯,是的,也許我會先回答最後一個問題。是的,你看,我們很高興能拿到資產負債表。顯然,出於多種原因,這是我們去年重點關注的問題。買個大的,給我們留點緩衝空間。環境非常非常難以預測,我們希望確保無論外部環境發生什麼,我們都能執行我們的優先事項。

  • And so as part of that, as a consequence, we’ve done a great -- the team has done a great job of increasing efficiencies and driving really tight cost management and in a good place now. Also, it gives us, like, a really strong position and ability to deploy capital as necessary as we look at kind of the landscape of opportunities out there.

    因此,作為其中的一部分,我們取得了巨大的成功——團隊在提高效率和嚴格控製成本方面做得非常出色,現在我們處於一個良好的狀態。此外,這也賦予了我們強大的地位和能力,可以根據需要部署資本,從而掌握市場上的各種機會。

  • We’re always looking and evaluating kind of the landscape again. Don’t have any hard rules around where we might invest. Always driven by fundamentally kind of the strategy, looking to where the world is going, what are the big opportunities, what are the big questions that need answering, and then determining what technology needs to be built, what products need to be built in the service of that. And kind of that’s what drives our investment philosophy, and again, good to be in a place where we have the resources to pursue this -- our strategies.

    我們一直在觀察和評估各種情況。對於投資方向,我們沒有任何硬性規定。始終以策略為根本驅動力,著眼於世界的發展方向、重大機會、亟待解決的重大問題,然後確定需要開發哪些技術、需要開發哪些產品來服務這些目標。而這正是我們投資理念的驅動力,而且,很高興我們身處一個擁有資源來推行這些策略的地方。

  • Adam Taich - Chief Financial Officer

    Adam Taich - Chief Financial Officer

  • I can take the -- or at least give you some thoughts, Dan, on the price volume as it relates to Chromium. And again, we thought kind of coming back to our guidance philosophy and trying to provide information that we think is useful, so for modeling and understanding our business. The reason that we provided kind of at the midpoint, we’re thinking about Chromium consumables as flat.

    丹,我可以談談——或者至少可以給你一些關於鉻的價格成交量的想法。我們再次想到,應該回歸我們的指導理念,努力提供我們認為有用的信息,以便對業務進行建模和理解。我們在中間部分給出的理由是,我們將鉻的消耗品視為扁平的。

  • There’s a bunch of different combinations and ways that you can get there. I guess what I would share with you, sort of again, is in Q4, 30%-plus reaction growth in the Chromium business grew 3%. We’re not suggesting -- obviously, what I’m telling you at the midpoint, that the Chromium business on the consumables is flat. Not suggesting that it’s gonna be plus 30, down 30. There’s a bunch of different ways we can get there, and given the underlying complexity of the portfolio, we certainly have been trying to do our best to communicate that.

    有很多不同的組合和方法可以到達那裡。我想再次和大家分享的是,在第四季度,鉻業務的反應成長率超過 30%,而實際成長率卻達到了 3%。我們並不是說——顯然,我剛才在中點告訴你們的是——鉻在耗材領域的業務停滯不前。並不是說漲跌幅會是30度。有很多不同的方法可以實現這一目標,考慮到投資組合的複雜性,我們當然一直在盡力傳達這一點。

  • But Flex Apex just came out. We had barely a stub of a quarter in Q4. Good trends here early in Q1, and a lot of that, both on the price side, given the mix of product and product price, as well as the volume, is really gonna play out during the course of the year. And even on an internal basis, we can see sort of how that could play out. That’s really part of the range of the guide that we’ve provided.

    但Flex Apex剛剛發布。第四季我們幾乎沒賺到一分錢。第一季初的趨勢不錯,考慮到產品組合和產品價格,以及銷量,價格方面有很多因素都會在今年內充分體現。即使在內部,我們也能大致看出這可能會如何發展。這確實是我們提供的指南內容的一部分。

  • Operator

    Operator

  • Patrick Donnelly, Citi.

    派崔克唐納利,花旗銀行。

  • Patrick Donnelly - Analyst

    Patrick Donnelly - Analyst

  • Adam, maybe some for you just on the guidance. Can you just talk about the confidence on the spatial piece? It sounds like you guys are talking about good growth there. Just that shift with Xenium and Visium, it sounds like Xenium is picking up a little bit. So, yeah, if you could just talk about that, it would be really helpful. Then you did mention the cost profile kind of strengthening up. If you could put anything around the margins, that would be helpful.

    亞當,或許你可以得到一些指導。能談談您對空間構圖的信心嗎?聽起來你們那邊發展勢頭良好。就 Xenium 和 Visium 的這種轉變而言,聽起來 Xenium 似乎略有起色。所以,如果你能談談這件事,那就太好了。然後你確實提到了成本結構有所改善。如果能在頁邊空白處添加一些文字,那就太好了。

  • Adam Taich - Chief Financial Officer

    Adam Taich - Chief Financial Officer

  • Let me start sort of on the spatial side. Yeah, we had a very strong year on spatial consumables in 2025, driven entirely by the Xenium franchise. So, Visium, just full disclosure, in 2025, didn’t grow. So all of the growth that you’re seeing in the spatial consumable side of things comes and more from the Xenium side of the business. Customer sentiment’s incredibly strong, utilization rates are fantastic.

    讓我先從空間方面談起。是的,2025 年我們在空間消耗品方面取得了非常強勁的成績,這完全得益於 Xenium 系列產品的推動。所以,坦白說,Visium 在 2025 年並沒有成長。所以,你在空間消費領域看到的所有成長,以及更多來自 Xenium 業務的成長。客戶情緒非常高漲,利用率也十分出色。

  • I think as we’ve discussed before, we’ve got customers that run them around the clock and have to go sort of expand their fleet. We’ve still got new customers buying in. Even in a CapEx-constrained environment we’ve been able to do an admirable job. Sales team’s doing a really good job getting instruments out there. So feel confident where we are on the spatial consumables number, that we can hit double-digit growth again here in 2026.

    我認為正如我們之前討論過的,我們有一些客戶全天候運營這些車輛,他們不得不擴大車隊規模。我們仍然有新客戶購買商品。即使在資本支出受限的環境下,我們也能夠出色地完成工作。銷售團隊在產品推廣方面做得非常出色。因此,請對我們目前的空間消耗品數量充滿信心,我們有信心在 2026 年再次實現兩位數的成長。

  • I think just broadly to your question on cost, yeah, it’s really important for us just to ensure that we’re deploying the resources wisely. We spent a lot of time in 2025 really ensuring that we’re making moves to strengthen our balance sheet. We were successful in that regard with cash up $130 million from the end of 2024 to where we are right now. And you’ll continue to see that type of cost discipline here in the company as we move into 2026.

    我認為,就你提出的成本問題而言,是的,對我們來說,確保我們明智地部署資源非常重要。2025年,我們投入了大量時間,確保採取措施加強我們的資產負債表。在這方面,我們取得了成功,從 2024 年底到現在,現金增加了 1.3 億美元。進入 2026 年,您將繼續在公司看到這種成本控制措施。

  • Operator

    Operator

  • Mason Carrico, Stephes Inc.

    Mason Carrico,Stephes 公司

  • Mason Carrico - Equity Analyst

    Mason Carrico - Equity Analyst

  • Last year you gave full year reaction numbers for Chromium, Visium, and Xenium. It seems like you guys chose to not give that this year. Could you just give some color on Xenium reagent growth in 2025? It’d be helpful to gain some insight in the utilization trends there. And then you guys have answered a handful of questions on Flex, but have you talked about the adoption cadence? I mean, are you expecting the transition to be a more gradual migration or more front-end loaded this year?

    去年您提供了鉻、維斯和澤尼姆的全年反應數據。看來你們今年選擇不捐贈了。能否簡單介紹一下 Xenium 試劑在 2025 年的發展前景?了解當地的利用趨勢會很有幫助。你們已經回答了一些關於 Flex 的問題,但你們有沒有談到採用節奏呢?我的意思是,您預計今年的過渡會是一個更漸進的過程,還是會是一個前期集中推進的過程?

  • Serge Saxonov - Chief Executive Officer, Co-Founder, Director

    Serge Saxonov - Chief Executive Officer, Co-Founder, Director

  • Mason, yeah, let me just take the Flex question first. I mean, the short answer is, like, it’s a little too early to tell. Like I said earlier, I just said, we didn’t even have a full quarter in Q4 of Flex Apex adoption. Clearly, there’s a lot of pent-up demand, and that has been really great to see. There’s also been great feedback coming back from customers who are actually adopting it and using it. And there’s a lot of interest on ramping up and especially ramping up new kinds of experiments that people weren’t contemplating before. But again, it’s just too early. All the early signs are encouraging, but it’s still too early to talk about, like the very specifics of the cadence.

    Mason,好的,那我先來回答關於Flex的問題吧​​。我的意思是,簡單來說,現在下結論還為時過早。正如我之前所說,我們甚至沒有在第四季度完成 Flex Apex 的採用。顯然,市場存在著大量被壓抑的需求,真是令人欣喜。此外,實際採用和使用該產品的客戶的回饋也非常好。人們對擴大規模,特別是擴大規模開展以前從未考慮過的新型實驗表現出了濃厚的興趣。但是,現在還是太早了。早期跡象令人鼓舞,但現在談論節奏的具體細節還為時過早。

  • Adam Taich - Chief Financial Officer

    Adam Taich - Chief Financial Officer

  • And yes, you’ll see when we, when the 10-K hits the wire, the reactions to your question there, and I think it was specific around Xenium. So Xenium reactions were 14,500 for the year, and that was up about 34% over prior year. And like I said, that’ll be in the 10-K.

    是的,當 10-K 報告發佈時,你會看到對你問題的反應,我認為它特別提到了 Xenium。所以,Xenium 全年的反應次數為 14,500 次,比前一年增長了約 34%。就像我說的,那將會是10公里賽程的一部分。

  • Operator

    Operator

  • Subbu Nambi, Guggenheim Securities.

    Subbu Nambi,古根漢證券。

  • Subbu Nambi - Equity Analyst

    Subbu Nambi - Equity Analyst

  • Looking ahead to AGPD, how are you thinking about competitive dynamics from some other players launching solutions this year? And what levers can you pull to stay ahead from a share perspective? Are there any competitive pressures baked into guidance at this point?

    展望即將到來的AGPD,您如何看待今年其他一些廠商推出解決方案所帶來的競爭格局?那麼,從市場佔有率的角度來看,你可以採取哪些措施來保持領先地位?目前的指導意見中是否存在任何競爭壓力?

  • Serge Saxonov - Chief Executive Officer, Co-Founder, Director

    Serge Saxonov - Chief Executive Officer, Co-Founder, Director

  • Yeah, so like, look, we feel really good about our position in the business and both in spatial and single cell. We have -- as you look at what has been happening kind of recently, the last several quarters, it’s been kind of a similar story pretty consistently where not much when you look at spatial, but really not much of an effect on our business. Clearly, Xenium is growing really fast, much faster than sort of other offerings out there from a much higher base.

    是的,所以你看,我們對我們在該行業的地位,以及在空間和單細胞領域的地位,都感到非常滿意。縱觀最近幾季發生的事情,情況一直都差不多,從空間角度來看並沒有太大變化,但對我們的業務影響卻不大。顯然,Xenium 的成長速度非常快,比市面上其他同類產品成長速度快得多,而且其基數也高得多。

  • We -- as we go forward, feel really good about our competitive position, both with respect to current competition and as well as any potential competition out that’s out there. We’ve been innovating continuously over the past several years and extending the gap between us and other potential offerings. And we certainly, again, we keep a pretty good pulse about what’s happening out there in the landscape and in various products and and launches. And again feel quite good about where we are relative to the landscape.

    展望未來,我們對自身的競爭地位感到非常滿意,無論是在面對當前的競爭,或是面對未來可能出現的任何競爭。過去幾年,我們一直在不斷創新,並不斷拉大我們與其他潛在產品之間的差距。當然,我們也會密切關注市場動態,了解各種產品和新品發布的情況。再次對我們相對於周圍環境的位置感到非常滿意。

  • Operator

    Operator

  • Dan Leonard, UBS.

    丹‧倫納德,瑞銀集團。

  • Lu Li - Analyst

    Lu Li - Analyst

  • This is Lu for Dan. I think one question on Visium. Given that it didn’t grow in 2025, can you just update us in terms of the go-forward strategy on the platform? Any plan to bring it back to positive growth?

    這是丹的盧。我想問一個關於Visium的問題。鑑於該平台在 2025 年沒有成長,您能否向我們介紹一下該平台未來的發展策略?有什麼計劃能使其恢復正成長嗎?

  • Serge Saxonov - Chief Executive Officer, Co-Founder, Director

    Serge Saxonov - Chief Executive Officer, Co-Founder, Director

  • So, yeah, Visium is a good platform for quite a number of applications for our customer use cases. And we have been very diligent in making sure we support those customers and drive those applications, and we absolutely will continue to do that.

    是的,Visium 對於我們客戶的許多應用場景來說都是一個很好的平台。我們一直非常努力地確保為這些客戶提供支援並推動這些應用程式的發展,而且我們一定會繼續這樣做。

  • But that said, like I said earlier, we are learning more and more, like, with pretty strong defensiveness, that Xenium is really the best choice for spatial analysis for the vast majority of use cases. And we have been investing in the Xenium platform. We expect to keep doing that in the future. And, yeah, and that’s kind of how it’s going to I think to balance out going forward. A lot of growth going forward in Xenium and Visium will have its place.

    但話雖如此,就像我之前說的,我們越來越認識到,而且非常堅定地認為,對於絕大多數用例來說,Xenium 確實是空間分析的最佳選擇。我們一直在投資 Xenium 平台。我們預計未來會繼續這樣做。是的,我認為未來會以這種方式達到平衡。未來 Xenium 和 Visium 將迎來很多成長,它們也將佔有一席之地。

  • Operator

    Operator

  • Michael Reiskind, Bank of America.

    邁克爾·雷斯金德,美國銀行。

  • Michael Ryskin - Analyst

    Michael Ryskin - Analyst

  • Maybe a boring one, but your comments about the timing shift or the pacing through 2026, I think you called out 1Q to be larger compared to prior years because of the orders late in the fourth quarter. Just could you just expand on that a little bit? Like anything in particular that stood out there, just relative to your comments on budget flush with one customer and to your product line?

    或許有點枯燥,但你對時間調整或到 2026 年的步伐的評論,我認為你提到第一季度比往年規模更大,是因為第四季度末的訂單。能再詳細解釋一下嗎?就您之前關於預算充足、只有一個客戶以及您的產品線的評論而言,有沒有什麼特別突出的地方?

  • Just a little bit unusual if you guys had such a meaningful swing. Just kind of want to get a sense of what that’s attributed to. Maybe was there any additional price you gave to capture those orders, just color around that would be helpful.

    如果你們的揮棒動作如此精彩,那就有點不尋常了。我只是想了解一下這指的是什麼。或許你為了拿下這些訂單而額外支付了什麼費用?如果能把這部分資訊標出來就更好了。

  • Adam Taich - Chief Financial Officer

    Adam Taich - Chief Financial Officer

  • Sure. Yeah, I can take that one, Mike. Yeah, I guess the last part, not really a pricing dynamic. We did mention, I think at an investor conference in January, that we did see some unanticipated budget flush, which is part of the reason that we ended up beyond the guide that we had set. Some of those orders that came in, in late December, we weren’t able to fulfill until January. So that was $2 million that essentially carried over and spilled into Q1.

    當然。是的,我可以應付,麥克。是的,我想最後一部分,其實不屬於定價因素。我想我們在一月份的投資者會議上提到過,我們確實看到了一些意料之外的預算盈餘,這也是我們最終超出預期目標的部分原因。12 月下旬收到的一些訂單,我們直到 1 月才能完成。所以,這200萬美元基本上結轉到了第一季。

  • So that’s part of what gives us confidence, although it’s a fairly small number for Q1. And then again, we’re a good way into Q1. The way we’re thinking about the quarter is historically, we’ve been 23% or so in Q1. If you think about sort of the full year, probably be about a point higher than that, so closer to 24%, as we think about Q1 as a percent of where we are, if you’re thinking about that at the midpoint of the guide.

    所以,這在某種程度上給了我們信心,儘管第一季這個數字相當小。而且,我們已經進入第一季的很大一部分時間了。我們對本季的看法是,從歷史數據來看,我們第一季的成長率大約在 23% 左右。如果從全年來看,可能會比這高出一個百分點,接近 24%,因為我們把第一季占我們目前狀況的百分比看作是指南的中點。

  • Operator

    Operator

  • Luke Sergott, Barclays.

    盧克·瑟戈特,巴克萊銀行。

  • Salem Salem - Analyst

    Salem Salem - Analyst

  • This is Salem Salem for Luke. Thanks for taking our questions. Just wanted a quick update on the timing of the scale technology integration. Are the expectations to kind of retain roughly the same throughput that scale on its own can achieve, while retaining the same quality of the legacy 10x technology? And are you able to kind of use the proposition of this new sort of integration to win over these new AI customers now with kind of the promise of providing something even higher throughput down the line?

    這是路加福音中的塞勒姆。謝謝您回答我們的問題。想快速了解規模化技術整合的時間安排。預期是在保持與傳統 10 倍技術相同品質的同時,大致保持與規模化本身所能達到的相同吞吐量嗎?你們能否利用這種新型整合方案,承諾未來提供更高吞吐量的服務,進而贏得這些新的人工智慧客戶?

  • Serge Saxonov - Chief Executive Officer, Co-Founder, Director

    Serge Saxonov - Chief Executive Officer, Co-Founder, Director

  • Yes. So first of all, on the question of sort of AI customers and those applications, the -- like predominantly, the right solution there is Flex Apex. That’s resonating really, really well for a number of reasons. It’s incredibly scalable, it has huge sensitivity, like really, really good sensitivity, it’s really robust, works across many different cell types and tissues. There’s a lot of kind of technical reasons, but it is just a really, really great product.

    是的。首先,關於人工智慧客戶和這些應用的問題,——主要是,Flex Apex 是正確的解決方案。這引起了很多方面的共鳴。它具有極強的可擴展性,靈敏度極高,靈敏度真的非常好,而且非常穩健,適用於多種不同的細胞類型和組織。有很多技術方面的原因,但它確實是一款非常非常棒的產品。

  • And again, there have been papers and there’s now been preprints that have been coming out, just validating just it’s really perfectly suited for that. As far as the scale technology is concerned, so what is going on in the market, as we’ve said that before, like on the kind of on the spectrum of our overall revenue, it is not really material. And we are obviously excited about the technology that the scale brings to us and incorporating it into future products. We haven’t yet talked about what those future products are, but there is definitely great potential and in due time we’ll talk about.

    而且,已經有一些論文和預印本發表,證實了它確實非常適合這項工作。就規模技術而言,正如我們之前所說,市場上的情況,就我們整體收入而言,並不重要。我們顯然對規模化帶來的技術感到興奮,並希望將其融入未來的產品中。我們還沒有討論過未來的產品是什麼,但它們肯定具有巨大的潛力,我們會在適當的時候進行討論。

  • Operator

    Operator

  • Casey Woodring, JPMorgan.

    Casey Woodring,摩根大通。

  • Casey Woodring - Analyst

    Casey Woodring - Analyst

  • Maybe first one, I wanted to dig into your plan to set up a CLIA lab. Can you maybe talk more about which indications you plan to target first and the timing of -- excuse me, generating clinical evidence for these diagnostics applications and actually standing up the lab and going through all the certifications and all that?

    首先,我想深入了解您建立 CLIA 實驗室的計劃。您能否詳細談談您計劃首先針對哪些適應症,以及——抱歉,我是說,為這些診斷應用生成臨床證據,實際建立實驗室,完成所有認證等等的時間安排?

  • And then how should we think about the CapEx required to build out the lab and that return on investment over time? And maybe just as a follow-up to that piece, how should we think about potential impact from diagnostics customers that are seeing 10x enter as a competitor?

    那麼,我們該如何考慮建造實驗室所需的資本支出以及長期的投資報酬率呢?或許可以作為那篇文章的後續探討,我們該如何看待診斷客戶看到 10 倍成長的競爭對手進入市場可能帶來的影響?

  • Serge Saxonov - Chief Executive Officer, Co-Founder, Director

    Serge Saxonov - Chief Executive Officer, Co-Founder, Director

  • Yeah, I mean, good question. So these are -- yeah, very good thematic questions here. One, maybe just to step back, just want to emphasize that are we excited about this direction? A lot of it driven by, again, the interest from our customers and just generally physicians out there. We believe there’s huge potential in clinical applications of single-cell and spatial. It is -- we’re starting to make, some initial investments and efforts along this direction. They’re early. They’re really for the future.

    嗯,問得好。所以,這些都是非常好的主題性問題。首先,或許該退一步,我想強調一下,我們對這個方向感到興奮嗎?這很大程度上是由我們客戶以及廣大醫生的興趣所驅動的。我們相信單細胞和太空技術在臨床應用方面具有巨大的潛力。是的——我們已經開始朝著這個方向進行一些初步的投資和努力。他們來得早。它們真的是為了未來而設計的。

  • One great thing is that we have a lot of assets, both in terms of technology, in terms of our position in the research market, in terms of the infrastructure we have here, where building up clinical evidence is actually really, really efficient for us, and we can do this in a way that doesn’t really materially impact our P&L. Our strategy is a hybrid strategy, where we absolutely are going to enable customers to develop clinical tests in the future. We’re working with quite a number of them right now, help them generate clinical evidence, help them deploy those tests, the necessary tests in the future.

    一件好事是,我們擁有很多資產,無論是在技術方面,還是在研究市場的地位方面,以及在我們這裡的基礎設施方面,積累臨床證據對我們來說實際上非常非常有效,而且我們可以以一種不會對我們的損益產生實質性影響的方式來做到這一點。我們的策略是混合策略,我們絕對會幫助客戶在未來開發臨床試驗。我們目前正在與許多這樣的機構合作,幫助他們產生臨床證據,幫助他們部署這些測試,以及未來必要的測試。

  • But again, we also believe we are in a unique position for some applications to really accelerate their arrival, and to drive impact sooner and faster than they otherwise would have been possible. Because again, we have all these assets that we can deploy in a really, really cost-effective manner to do that. We talked about two big applications specifically for tissue-based tumor profiling to guide the therapy selection for, like, all these new generations of therapeutics that are coming -- that are now coming online that are targeting different expression markers.

    但同樣,我們也相信,我們處於一個獨特的地位,可以真正加速某些應用程式的到來,並比其他方式更快地產生影響。因為我們擁有所有這些資源,可以以非常經濟高效的方式部署這些資源來實現這一目標。我們討論了組織腫瘤分析的兩大應用,特別是指導治療選擇,例如所有即將推出的新一代療法——這些療法現在正針對不同的表達標記物上線。

  • And also a blood. We talked about an application of using single cell for blood to guide monitoring and treatment selection for autoimmune diseases. Another really, really big and exciting application.

    還有血液。我們討論了利用血液中的單一細胞來指導自體免疫疾病的監測和治療選擇的應用。又一個非常非常龐大且令人興奮的申請。

  • So, again, these are efforts all aimed towards the future. We have set out to build a CLIA lab, and we’re targeting early next year to stand it up. Again, we believe we can do it very, very efficiently and make use of a lot of the assets we already have. And in that sense, it’s going to be very minor impact on our P&L.

    所以,再次強調,這些努力都是為了未來。我們已著手建造一個符合 CLIA 標準的實驗室,目標是在明年初完成。我們再次相信,我們可以非常有效率地完成這項工作,並充分利用我們已有的大量資產。從這個意義上講,它對我們的損益表的影響將非常小。

  • Operator

    Operator

  • Matt Larew, William Blair.

    馬特拉魯,威廉布萊爾。

  • Matt Larew - Analyst

    Matt Larew - Analyst

  • Wanted to follow up on AI, and one is for Adam, which is if you could quantify at all either revenue orders related to AI in '25 or the expectation in '26. The second part, Serge, is for you, which is, I guess, a bit higher level. It sounds like demand right now is in service of the larger projects, Virtual Cell foundation models. I guess I’m curious if you expect that work, that demand to be iterative over time, where customers are constantly building models based in part on large perturbation sets, rather than sort of a one and done. That’s kind of the first part.

    想跟進一下人工智慧方面的問題,其中一個問題是問 Adam 的,那就是你是否可以量化 2025 年與人工智慧相關的收入訂單,或是 2026 年的預期收入訂單。塞爾吉,第二部分是給你的,我想,這部分難度更高。聽起來目前的需求主要服務於大型專案和虛擬單元基礎模型。我很好奇你是否期望這項工作、這種需求會隨著時間的推移而不斷迭代,客戶會不斷地基於大量擾動集來建立模型,而不是一次性完成。那算是第一部分。

  • Last year there were some papers out around the idea of in silico perturbation, so I’m curious how you see that complementing or competing. Then the third, I guess, higher level on Serge is, you have a network of CRO partners around the world, and certainly 10x can. You’re an expert user of your own product.

    去年有一些關於電腦模擬擾動的論文發表,所以我很好奇您認為它與電腦模擬擾動有何互補或競爭關係。然後,我認為 Serge 的第三個更高層次的優勢在於,你擁有遍布全球的 CRO 合作夥伴網絡,而且肯定可以達到 10 倍的效果。您是自己產品的專家使用者。

  • So just as you have some of these more non-traditional companies or groups of people entering the space and building models, maybe if the customer group might shift at all for your products, and maybe if that alleviates the capital constraints that some smaller customers might face if it becomes more outsourced. So I understand there’s a lot there, but I guess one is the near term opportunity, and then the bigger one, Serge, is how you see the space playing out over time.

    因此,就像一些非傳統的公司或團體進入該領域並建立模式一樣,如果客戶群發生一些變化,你的產品或許就能緩解一些小型客戶在業務更多地外包時可能面臨的資金限制。所以我知道這裡面有很多因素,但我想其中之一是近期的機會,而更大的問題,Serge,是你如何看待這個領域隨著時間的推移而發展。

  • Serge Saxonov - Chief Executive Officer, Co-Founder, Director

    Serge Saxonov - Chief Executive Officer, Co-Founder, Director

  • Yeah. So maybe I’ll start there. First of all, in terms of kind of providing potential service offerings to customers, if they kind of want to generate very large data sets, that’s certainly something that has been on our minds and that we’ve -- we certainly had people come to us. And we do have some service offerings, that could potentially play a larger role in the future, as we think about this.

    是的。所以也許我會從那裡開始。首先,就向客戶提供潛在服務產品而言,如果他們想要產生非常大的資料集,這當然是我們一直在考慮的事情,而且我們——確實有人來找過我們。我們確實有一些服務產品,考慮到這一點,這些產品未來可能會發揮更大的作用。

  • The bigger stepping back, the bigger part of your question around potential for AI and how will it evolve? Yeah, like I think very much, back to kind of your first framing, where we see this as a continuous kind of growth in demand and scale. I don’t think there’s anyone who thinks that we are anywhere near the scale we need, and that there’s going to be any less usefulness to joining more of our data where we currently are.

    退後一步,你提出的問題中關於人工智慧的潛力以及它將如何發展的部分就顯得更重要了?是的,我覺得這很符合你最初的設想,即需求和規模會持續成長。我不認為有人會認為我們目前的規模已經接近所需規模,也不認為在我們目前擁有的範圍內,整合更多數據會減少其用途。

  • So I think we’re just at the very early stages of the sort of the scaling revolution for generating AI. It’s sort of very analogous to what has happened in other domains where AI has been applied, and there is good reasons to think why it might be even more relevant and powerful for these kinds of biological data sets, where the complexity is just enormous.

    所以我認為我們目前還處於人工智慧生成規模化革命的早期階段。這與人工智慧在其他領域應用的情況非常相似,而且有充分的理由認為,對於這類複雜性龐大的生物數據集而言,人工智慧可能更加相關和強大。

  • And then sort of the second kind of part of your, like, framing there was whether in silico experiments can at some point replace some of the sort of biological data generation. And, I -- yeah, I think a very strong view. I think it’s very hard to argue with the fact that biology is just, like, insanely complex, and we’re very, very, very far from understanding it.

    然後,你提出的第二個問題,就像是,電腦模擬實驗能否在某種程度上取代某些生物數據產生方式。而且,我——是的,我認為這是一個非常強烈的觀點。我認為很難反駁生物學極其複雜,而且我們距離理解它還非常非常遙遠。

  • If we start getting close to the point where we’re actually, like, solving biology, then okay, but we are, like, very, very far away from it. And so, the runway here is enormous. We need to generate lots and lots of data, and I don’t think there’s anyone who would materially disagree with that premise.

    如果我們開始接近真正解決生物學問題的那個階段,那當然很好,但我們離那個階段還非常非常遠。所以,這裡的跑道非常長。我們需要產生大量的數據,我認為沒有人會對此前提提出實質的異議。

  • And maybe I’ll just pick up that last, that first bit of the question on like, in terms of how much demand is driving right now. I kind of mentioned earlier, I mean, it’s meaningful. We talked about very large projects last year that have been running, that have been gearing up, but still a relatively small percentage of the business. We do expect all this to grow, and a lot of it is actually being driven by Flex Apex. It is the perfect assay for all these projects, for driving perturbation screening, for doing it across many different cell types and tissues. But it’s still very, very early days. Like I said earlier, what’s particularly exciting here is that as we look to the future, there is really no cap to the upside here.

    也許我會就問題的最後一部分,也就是第一部分,談談目前的需求驅動力有多大。我之前也提到過,我的意思是,這很有意義。去年我們討論過一些規模非常大的項目,這些項目一直在進行、正在籌備中,但仍然只佔業務的一小部分。我們預計這一切都會發展壯大,而其中許多實際上是由 Flex Apex 推動的。它是所有這些項目的完美檢測方法,可用於驅動擾動篩選,並可用於在許多不同的細胞類型和組織中進行篩選。但現在還為時過早。正如我之前所說,這裡特別令人興奮的是,展望未來,這裡的上漲空間真的沒有上限。

  • Operator

    Operator

  • There are no further questions at this time. With that being said, we’ll conclude today’s conference call. We thank you all for joining. You may now disconnect.

    目前沒有其他問題了。綜上所述,我們今天的電話會議就到此結束。感謝各位的參與。您現在可以斷開連線了。